Cargando…
Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
Tamoxifen therapy resistance constitutes a major cause of death in patients with recurrent estrogen receptor (ER) positive breast cancer. Through high resolution mass spectrometry (MS), we previously generated a 4-protein predictive signature for tamoxifen therapy outcome in recurrent breast cancer....
Autores principales: | De Marchi, Tommaso, Timmermans, Anne M., Smid, Marcel, Look, Maxime P., Stingl, Christoph, Opdam, Mark, Linn, Sabine C., Sweep, Fred C. G. J., Span, Paul N., Kliffen, Mike, van Deurzen, Carolien H. M., Luider, Theo M., Foekens, John A., Martens, John W., Umar, Arzu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823093/ https://www.ncbi.nlm.nih.gov/pubmed/26657294 http://dx.doi.org/10.18632/oncotarget.6521 |
Ejemplares similares
-
4‐protein signature predicting tamoxifen treatment outcome in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015) -
Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2017) -
Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients
por: Liu, Ning Qing, et al.
Publicado: (2016) -
Proteomic characterization of microdissected breast tissue environment provides a protein‐level overview of malignant transformation
por: Braakman, René B. H., et al.
Publicado: (2017) -
Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer
por: Umar, Arzu, et al.
Publicado: (2009)